Hepatitis C is a growing epidemic.
According to the Centers for Disease Control and Prevention (CDC), an estimated 3.2 million people in the United States have chronic hepatitis C (HCV); yet most are unaware of their infection because they feel and look healthy.
Chronic hepatitis C can progress more rapidly in individuals with an HIV infection. In fact, the CDC estimates that approximately one quarter of those living with HIV/AIDS also live with the hepatitis C virus. Co-infection with these two viruses can result in poor health outcomes, treatment complications and faster progression to liver disease.
Through testing, prompt treatment, and regular monitoring by an experienced physician, individuals infected with HCV may be able to avoid the long-term burden of care related to liver failure, cancer, and transplants. Harborpath now offers Merck's Zepatier to qualified uninsured individuals diagnosed with hepatitis C.
To learn more about how to access resistance testing at no cost click:
ADAP Waiting List Program
HarborPath administers the AIDS Drug Assistance Program (ADAP) Waiting List Program, in which patients who are on their state’s ADAP Waiting Lists receive antiretroviral medications donated by pharmaceutical manufacturers. Learn more about the HarborPath ADAP Waiting List Program and enroll your eligible patients living with HIV/AIDS.